On December 1, 2015 Celator Pharmaceuticals, Inc. (Nasdaq:CPXX) reported that data for VYXEOS (formerly CPX-351), its lead product candidate, will be presented at the 57th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition in Orlando, December 5-8, 2015 (Press release, Celator Pharmaceuticals, DEC 1, 2015, View Source [SID:1234508370]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abstracts selected for poster presentation are:

Date: Sunday, December 6, 2015, 6:00 p.m. – 8:00 p.m.
Presentation Title: CPX-351 ((Cytarabine:Daunorubicin) Liposome Injection, (Vyxeos)) Does Not Prolong QTcF Intervals, Requires No Dose Adjustment for Impaired Renal Function and Induces High Rates of Complete Remission in Acute Myeloid Leukemia
Presenter: Dr. Tara Lin
Abstract Number: 2510
Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster II
Location: Hall A (Orange County Convention Center)

Date: Monday, December 7, 2015, 6:00 p.m. – 8:00 p.m.
Presentation Title: CPX-351 Enables Administration of Consolidation Treatment in the Outpatient Setting and Increases the Time Spent out of the Hospital after Completion of AML Treatment Compared with 7+3
Presenter: Dr. Jeffrey Lancet
Abstract Number: 4507
Session: 902. Health Services and Outcomes Research – Malignant Diseases: Poster III
Location: Hall A (Orange County Convention Center)